Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Halia Therapeutics Inc. has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are being handled by 2 distinct examiners, providing the company with different points of review for its current applications. This variety in examiners can result in different prosecution styles being applied to the company's pharmaceutical claims.
The prosecution is further divided across 2 distinct art units. This separation suggests that the company's biotechnology and pharmaceutical filings are being evaluated by different specialized technical groups, rather than being centralized in one unit. Navigating multiple art units requires a flexible approach to meet the specific technical expectations of each group.
KENYON, JOHN S is the busiest examiner for the portfolio with 1 busiest examiner pending action. Because the company has 2 pending office actions and 2 distinct examiners, the workload is distributed across the assigned staff. This parity means that no single examiner has a disproportionate impact on the company's current pending matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KENYON, JOHN S | 1 | 79.7% | +18.3% |
| VAJDA, KRISTIN ANN | 1 | 84.0% | +10.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18262787 | NEK7 INHIBITORS | VAJDA, KRISTIN ANN | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18699841 | TYRO3 INHIBITORS | KENYON, JOHN S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18699841 | TYRO3 INHIBITORS | KENYON, JOHN S | — |
| 18262787 | NEK7 INHIBITORS | VAJDA, KRISTIN ANN | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18699841 | TYRO3 INHIBITORS | KENYON, JOHN S | 1625 | §102§112 | Non-Final OA | — | Pending | Apr 09, 2024 |
| 18262787 | NEK7 INHIBITORS | VAJDA, KRISTIN ANN | 1622 | §112 | Non-Final OA | — | Pending | Jul 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial